[ad_1]
Scientists have developed a method to provide genetic material to treat damaged kidney cells in mice, a breakthrough that could lead to gene therapy to cure life-threatening chronic kidney disease (CDK) in children. ;man. Harvard University and the Mbadachusetts Institute of Technology (MIT) in the United States, discovered that gene therapy can slow or even reverse kidney damage, thereby preventing chronic kidney disease – gradual loss of kidney function for many years. months or years.
"Chronic renal disease is a huge and growing problem Unfortunately, over the years, we have not developed more effective drugs for this disease, and this reality leads us to explore gene therapy", said Benjamin D Humphreys. author of the study published in the Journal of the American Society of Nephrology
Diabetes, hypertension and other conditions cause CKD, which occurs when damaged kidneys can not not effectively filter waste and excess fluids from the body. In some cases, it is also known to lead to cardiovascular disease.
Most people do not realize that they have chronic kidney disease until irreparable damage occurs because of symptoms such as nausea, vomiting, sleep disturbances and limbs swollen are common. According to the researchers, the research was focused on whether the adeno-badociated virus (AAV) – a parent of the virus that causes colds – could provide genetic material to targeted kidney cells.
Scientists evaluated six naturally occurring and synthetic AAV viruses in mice and human stem cell-derived kidney organoids.
A synthetic virus, Anc80, created by one of the researchers managed to reach the cells that contribute to chronic
The researchers also showed that the genetic material carried by Anc80 was successfully transferred into the targeted kidney cells and that the same virus was also used by the researchers. "The interesting thing about adeno-badociated viruses is that they persist in the body for many months, which can give a therapeutic gene a chance to do its job," said Humphreys.
"Chronic kidney disease is a slowly progressive disease, which is a benefit.After many years of research, we could imagine that patients would need injections twice a year rather than weekly, as with chemotherapy, "he added.
The researchers warned however that the future will present several challenges, such as the need to identify a gene that can largely correct damaged kidney cells.
(This story was not edited by Business Standard staff and is generated automatically from a syndicated feed.)
[ad_2]
Source link
